KOD - Kodiak Sciences Inc.
About Kodiak Sciences Inc. (https://kodiak.com)
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | 1974 | $1,576,189 USD |
| John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | 1963 | $937,157 USD |
| Hong Liang | Senior Vice President of Development | 1972 | $300,709 USD |
| Almas Qudrat | Chief Quality Officer | – | – |
| Dolly S. Chang | Chief Scientific Officer | – | – |
| J. Pablo Velazquez-Martin | Chief Medical Officer | – | – |
| Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | – | – |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | – | – |
| Wayne To | Chief Technology Officer | – | – |